Literature DB >> 10533285

Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells.

R A Faust1, G Niehans, M Gapany, D Hoistad, D Knapp, D Cherwitz, A Davis, G L Adams, K Ahmed.   

Abstract

CK2 is a messenger-independent protein serine/threonine kinase that has been implicated in cell growth and proliferation. Our recent analysis of squamous cell carcinomas of the head and neck (SCCHN) revealed a significant elevation in CK2 activity in these tumor cells relative to normal mucosa of the upper aerodigestive tract and suggested a correlation with aggressive tumor behavior and poor clinical outcome. In order to further define the distribution of CK2 in these tissues, we have examined the immunohistochemical staining pattern of surgical specimens of both SCCHN tumors and normal upper aerodigestive tract mucosa using a monoclonal antibody directed against the catalytic subunit CK2-alpha of the kinase, and have compared these data with the subcellular distribution of CK2 activity in these same tissues. These measurements showed that CK2 is predominantly localized to the nuclei of the tumor cells, which agreed closely with the immunohistochemical staining pattern of CK2-alpha in tumor cells. The chiefly nuclear distribution of CK2-alpha immunostaining found consistently in SCCHN tumor cells and tumor-infiltrating lymphocytes contrasted with a relatively more predominant cytosolic staining pattern exhibited by various cellular constituents of normal oropharyngeal mucosa. The immunostaining pattern of CK2-alpha revealed that staining was observed in the cells stained for the proliferation-marker Ki-67; however, strong distinct immunostaining for CK2-alpha was also observed in large numbers of other cells in these same tumors, suggesting that CK2 elevation in these tumors is not a reflection of proliferative activity alone, but may also relate to the pathobiological behavior of the tumor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533285     DOI: 10.1016/s1357-2725(99)00050-3

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  28 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

2.  Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Authors:  Fatima Qaiser; Janeen H Trembley; Sarah Sadiq; Iqbal Muhammad; Rubina Younis; Shoaib Naiyar Hashmi; Badar Murtaza; Thomas S Rector; Abdul Khaliq Naveed; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

3.  Effect of DRB on the biological characteristics of human laryngeal carcinoma Hep-2 cell line.

Authors:  Jianting Wang; Shusheng Gong; Yong Fu; Qiuhong Xue; Guangli Chen; Yingpeng Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

4.  CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.

Authors:  Judit Pallares; David Llobet; Maria Santacana; Nuria Eritja; Ana Velasco; Dolors Cuevas; Susana Lopez; Victor Palomar-Asenjo; Andree Yeramian; Xavier Dolcet; Xavier Matias-Guiu
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

5.  Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironment.

Authors:  Jelena Vasilevska; Gustavo Antonio De Souza; Maria Stensland; Dace Skrastina; Dmitry Zhulenvovs; Raimonds Paplausks; Baiba Kurena; Tatjana Kozlovska; Anna Zajakina
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 6.  Protein kinase CK2--a key suppressor of apoptosis.

Authors:  Kashif A Ahmad; Guixia Wang; Gretchen Unger; Joel Slaton; Khalil Ahmed
Journal:  Adv Enzyme Regul       Date:  2008-04-30

7.  CK2 phosphorylation of SAG at Thr10 regulates SAG stability, but not its E3 ligase activity.

Authors:  Hongbin He; Mingjia Tan; Deepika Pamarthy; Guixia Wang; Khalil Ahmed; Yi Sun
Journal:  Mol Cell Biochem       Date:  2006-07-28       Impact factor: 3.396

8.  Response of cancer cells to molecular interruption of the CK2 signal.

Authors:  H Wang; A Davis; S Yu; K Ahmed
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

9.  Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Andrew D Hollenbach
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

Review 10.  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Authors:  J H Trembley; G Wang; G Unger; J Slaton; K Ahmed
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.